Log in

Relevant bibliographies by topics / Randomized MPC / Journal articles

To see the other types of publications on this topic, follow the link: Randomized MPC.

Journal articles on the topic 'Randomized MPC'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Randomized MPC.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Alotaibi, Abdullah, Jerrold Petrofsky, Noha S. Daher, Everett Lohman, Hasan M. Syed, and Haneul Lee. "The Effect of Monophasic Pulsed Current with Stretching Exercise on the Heel Pain and Plantar Fascia Thickness in Plantar Fasciitis: A Randomized Controlled Trial." Healthcare 8, no. 2 (2020): 79. http://dx.doi.org/10.3390/healthcare8020079.

Full text

Abstract:

Plantar fasciitis (PF) is one of the most common causes of heel and foot pain. Monophasic pulsed current (MPC) is an electrical stimulation used to accelerate the healing processes. The purpose of this study was to determine the effect of MPC and MPC combined with plantar fascia stretching exercises (SE) on heel pain and plantar fascia thickness in treatment of PF and see if there is any relationship between heel pain and plantar fascia thickness after intervention. Forty-four participants diagnosed with PF were randomly assigned to two group; MPC group or MPC combined with plantar fascia SE.

APA, Harvard, Vancouver, ISO, and other styles

2

Boehm, Johannes, Etienne Fize, and Xavier Jaravel. "Five Facts about MPCs: Evidence from a Randomized Experiment." American Economic Review 115, no. 1 (2025): 1–42. https://doi.org/10.1257/aer.20240138.

Full text

Abstract:

We present five facts from an experiment on the marginal propensity to consume (MPC) out of transitory transfers: (1) the one-month MPC on a cash-like transfer is 23 percent; (2) it is substantially higher (61 percent) on a transfer administered via a card where remaining funds expire after three weeks, inconsistent with money fungibility; (3) the consumption response is concentrated in the first three weeks; (4) MPCs vary with household characteristics but are high even for the liquid wealthy; (5) unconditional MPC distribution exhibits large variation. Our findings inform the design of stimu

APA, Harvard, Vancouver, ISO, and other styles

3

Chan, Alex H., Randall F. D'Souza, Joseph W. Beals, et al. "The Degree of Aminoacidemia after Dairy Protein Ingestion Does Not Modulate the Postexercise Anabolic Response in Young Men: A Randomized Controlled Trial." Journal of Nutrition 149, no. 9 (2019): 1511–22. http://dx.doi.org/10.1093/jn/nxz099.

Full text

Abstract:

ABSTRACT Background Resistance exercise and dietary protein stimulate muscle protein synthesis (MPS). The rate at which proteins are digested and absorbed into circulation alters peak plasma amino acid concentrations and may modulate postexercise MPS. A novel mineral modified milk protein concentrate (mMPC), with identical amino acid composition to standard milk protein concentrate (MPC), was formulated to induce rapid aminoacidemia. Objectives The aim of this study was to determine whether rapid aminoacidemia and greater peak essential amino acid (EAA) concentrations induced by mMPC would sti

APA, Harvard, Vancouver, ISO, and other styles

4

Kutschka, I., J. Skorpil, A. El Essawi, T. Hajek, and W. Harringer. "Beneficial effects of modern perfusion concepts in aortic valve and aortic root surgery." Perfusion 24, no. 1 (2009): 37–44. http://dx.doi.org/10.1177/0267659109106727.

Full text

Abstract:

Minimized perfusion circuits (MPC) were found to reduce side effects of standard extracorporeal circulation (ECC). We evaluated the safety and efficacy of the ROCsafe™ MPC for aortic valve and aortic root surgery. One hundred and seventy patients were randomized for surgery using either MPC [n = 85, 30 female/55 male, mean age: 69.8 ± 11.8 years; aortic valve replacement (AVR): n = 40; AVR + coronary artery bypass graft (CABG): n = 31; David operation: n = 3; aortic root replacement (ARR): n = 11] or ECC [n = 85, 29 female/56 male, mean age: 67.7 ± 9.5 years; AVR: n = 39; AVR+CABG: n = 35, Dav

APA, Harvard, Vancouver, ISO, and other styles

5

D’Eredità, Riccardo. "Molecular Resonance Tonsillectomy in Children." Otolaryngology–Head and Neck Surgery 151, no. 5 (2014): 861–67. http://dx.doi.org/10.1177/0194599814545458.

Full text

Abstract:

Objectives Learn the molecular resonance (MR) technology for tonsillectomy. An analysis of outcomes of MR compared to standard cold-knife (CK) and monopolar cautery (MPC) for pediatric tonsillectomy offers new possibilities, lowering postoperative morbidity. Study Design Eleven-year, prospective, randomized, 3-group trial. Setting Tertiary care pediatric institution. Subjects and Methods Eight hundred and seventy-three children undergoing adenotonsillectomy were randomly assigned to MR (n = 283), CK (n = 279), or MPC (n = 279) techniques. Outcome measures included intraoperative time, blood lo

APA, Harvard, Vancouver, ISO, and other styles

6

Fujiwara, Natsumi, Hiromichi Yumoto, Koji Miyamoto, et al. "2-Methacryloyloxyethyl phosphorylcholine (MPC)-polymer suppresses an increase of oral bacteria: a single-blind, crossover clinical trial." Clinical Oral Investigations 23, no. 2 (2018): 739–46. http://dx.doi.org/10.1007/s00784-018-2490-2.

Full text

Abstract:

Abstract Objectives The biocompatible 2-methacryloyloxyethyl phosphorylcholine (MPC)-polymers, which mimic a biomembrane, reduce protein adsorption and bacterial adhesion and inhibit cell attachment. The aim of this study is to clarify whether MPC-polymer can suppress the bacterial adherence in oral cavity by a crossover design. We also investigated the number of Fusobacterium nucleatum, which is the key bacterium forming dental plaque, in clinical samples. Materials and methods This study was a randomized, placebo-controlled, single-blind, crossover study, with two treatment periods separated

APA, Harvard, Vancouver, ISO, and other styles

7

El-Essawi, A., T. Hajek, J. Skorpil, et al. "Are minimized perfusion circuits the better heart lung machines? Final results of a prospective randomized multicentre study." Perfusion 26, no. 6 (2011): 470–78. http://dx.doi.org/10.1177/0267659111419035.

Full text

Abstract:

Introduction: Minimized perfusion circuits (MPCs), although aiming at minimizing the adverse effects of cardiopulmonary bypass, have not yet gained popularity. This can be attributed to concerns regarding their safety, as well as lack of sufficient evidence of their benefit. Methods: Described is a randomized, multicentre study comparing the MPC - ROCsafeRX to standard cardiopulmonary bypass in patients undergoing elective coronary artery bypass grafting and/ or aortic valve replacement. Results: Five hundred patients were included in the study (252 randomized to the ROCsafeRX group and 248 to

APA, Harvard, Vancouver, ISO, and other styles

8

O'Reilly, Eileen Mary, Vaibhav Sahai, Johanna C. Bendell, et al. "Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)." Journal of Clinical Oncology 35, no. 4_suppl (2017): 279. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.279.

Full text

Abstract:

279 Background: Tarextumab (TRXT), fully human IgG2 antibody inhibits signaling of Notch2/ 3 receptors. Tumor regression seen in Notch3 (N3) expressing pt-derived pancreatic cancer xenografts when TRXT combined with Nab-P+Gem. Phase 2, randomized, placebo-controlled trial conducted to evaluate efficacy, safety of combination in mPC. Methods: Pts randomized 1:1 to TRXT or placebo (PL). TRXT given IV at 15 mg/kg q 2wks (D 1, 15), nab-P 125 mg/m2, GEM 1000mg/m2 on D1, 8, 15 q 28 days. Tissue for N3 gene expression determination was required. Primary endpoints: overall survival (OS) in all and in

APA, Harvard, Vancouver, ISO, and other styles

9

Bozorgi, Mahbubeh, Shekoufeh Nikfar, Mohammad Abdollahi, and Roja Rahimi. "Effect of pistachio on plasma lipids concentration: a meta-analysis of randomized controlled trials." Medicinal Plant Communications 4, no. 1 (2021): 1–13. http://dx.doi.org/10.37360/mpc.21.4.1.01.

Full text

Abstract:

Dyslipidemia and lipoprotein metabolism disorder are involved in pathogenesis of many important diseases such as diabetes, atherosclerosis, acute pancreatitis, and malignancies. The present study aimed to evaluate the effect of pistachio on plasma lipids. Electronic databases including Scopus, Pubmed, Science Direct, and Cochrane library were searched with the keywords “lipoprotein”, “blood lipid”, “dyslipidemia” or “hyperlipidemia” with “Pistachio” until June 2019. Two review authors independently checked eligibility and extracted data using a standard form. Information extracted included cha

APA, Harvard, Vancouver, ISO, and other styles

10

Lu, Xin, Chunqing Huang, and Kejun Zhao. "Randomized Algorithm of Constrained MPC for Linear Systems with Bounded Additive Disturbances." IFAC Proceedings Volumes 45, no. 15 (2012): 667–72. http://dx.doi.org/10.3182/20120710-4-sg-2026.00165.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Gresham, Gillian, Sharlene Gill, George A. Wells, and Derek J. Jonker. "A network meta-analysis (NMA) of randomized controlled trials (RCT) of chemotherapy regimens for metastatic pancreatic cancer (mPC)." Journal of Clinical Oncology 31, no. 15_suppl (2013): 4050. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4050.

Full text

Abstract:

4050 Background: Recent RCTs suggest a survival benefit for combination therapy in mPC compared to gemcitabine alone. Such combinations include FOLFIRINOX and gemcitabine plus nab-paclitaxel (G+nab-P). Survival and safety outcomes of these regimens were analyzed using gemcitabine as the reference comparator. Methods: Systematic review and NMA included data from reported phase III RCTs meeting quality standards and compared chemotherapy treatment to gemcitabine for mPC between 2000 and 2013. Excluded were trials assessing locally advanced pancreatic cancer. Following inter-trial heterogeneity a

APA, Harvard, Vancouver, ISO, and other styles

12

Pusceddu, Sara, Michele Ghidini, Martina Torchio, et al. "Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis." Cancers 11, no. 4 (2019): 484. http://dx.doi.org/10.3390/cancers11040484.

Full text

Abstract:

Gemcitabine and nab-paclitaxel (GEM-NAB) and the combination of 5-fluorouracil, oxaliplatin, and irinotecan (FOLFIRINOX) are valid first-line options for advanced or metastatic pancreatic cancer (mPC). However, no randomized trials comparing the two schemes have been performed. This meta-analysis aims to compare GEM-NAB and FOLFIRINOX in terms of safety and effectiveness, taking into account data from real-life studies on mPC. We systematically searched PubMed, EMBASE and Cochrane library up to November 2018 to identify retrospective or cohort studies on mPC comparing GEM-NAB and FOLFIRINOX. W

APA, Harvard, Vancouver, ISO, and other styles

13

Ali, Kasiri Fereydoun Farrahi Mostafa Feghhi Behnam Sadeghi Hesam Hedayati Seyed Ahmad Rasoulinejad. "COMPARISON OF INTRAVITREAL BEVACIZUMAB (AVASTIN) WITH TRIAMCINOLONE FOR TREATMENT OF DIFFUSED DIABETIC MACULAR EDEMA: A PROSPECTIVE RANDOMIZED STUDY." Indo American Journal of Pharmaceutical Sciences 04, no. 11 (2017): 4483–91. https://doi.org/10.5281/zenodo.1067105.

Full text

Abstract:

Objectives: Despite the high prevalence of diabetic macular edema (DME), there is no definite treatment because of its complicated pathophysiologic mechanism, which is still not fully understood. This study was performed to compare the efficacy of intravitreal bevacizumab (IVB) with intravitreal triamcinolone acetonide (IVT) in patients exhibiting diffused DME. Methods: In this randomized clinical trial, eligible eyes were assigned randomly to one of the three study arms: the IVB group, patients who received 1.25 mg IVB (30 eyes); the IVT group, patients who received 2 mg of IVT (30 eyes); and

APA, Harvard, Vancouver, ISO, and other styles

14

Hammel, P., F. Mornex, G. Deplanque, et al. "Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: A multicenter phase II study." Journal of Clinical Oncology 27, no. 15_suppl (2009): 4617. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4617.

Full text

Abstract:

4617 Background: Masitinib, a tyrosine kinase inhibitor targeting c-Kit, PDGFR, FGFR3 and affecting the FAK pathway, can enhance the antiproliferative effects of gemcitabine (GEM) in human pancreatic cancer cells. This multicenter phase 2 study aimed to determine the efficacy and safety of masitinib in combination with GEM in the first-line treatment of patients with locally advanced (LAPC) or metastatic (MPC) pancreatic cancer. Methods: Patients received oral masitinib (9 mg/kg/d) and standard weekly infusion of GEM (1,000 mg/m2). Primary endpoint was time-to-progression (TTP). Our hypothesis

APA, Harvard, Vancouver, ISO, and other styles

15

Oehme, David, Peter Ghosh, Susan Shimmon, et al. "Mesenchymal progenitor cells combined with pentosan polysulfate mediating disc regeneration at the time of microdiscectomy: a preliminary study in an ovine model." Journal of Neurosurgery: Spine 20, no. 6 (2014): 657–69. http://dx.doi.org/10.3171/2014.2.spine13760.

Full text

Abstract:

Object Following microdiscectomy, discs generally fail to undergo spontaneous regeneration and patients may experience chronic low-back pain and recurrent disc prolapse. In published studies, formulations of mesenchymal progenitor cells combined with pentosan polysulfate (MPCs+PPS) have been shown to regenerate disc tissue in animal models, suggesting that this approach may provide a useful adjunct to microdiscectomy. The goal of this preclinical laboratory study was to determine if the transplantation of MPCs+PPS, embedded in a gelatin/fibrin scaffold (SCAF), and transplanted into a defect cr

APA, Harvard, Vancouver, ISO, and other styles

16

Chen, Inna Markovna, Julia S. Johansen, Susann Theile, et al. "Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC)." Journal of Clinical Oncology 40, no. 4_suppl (2022): 554. http://dx.doi.org/10.1200/jco.2022.40.4_suppl.554.

Full text

Abstract:

554 Background: Pancreatic ductal adenocarcinoma remains one of the most lethal diseases. Investigating novel treatment strategies for patients with metastatic pancreatic cancer (mPC) is crucial. The purpose of this phase II trial study was to evaluate the clinical benefit of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy (SBRT) in patients with mPC. Methods: Between November 2016 and December 2019, patients with refractory mPC were randomly assigned 1:1 to SBRT of 15 Gy with nivolumab or nivolumab/ipilimumab stratified by performance status. Primary en

APA, Harvard, Vancouver, ISO, and other styles

17

Kindler, Hedy L., Suvina Amin, Seongjung Joo, et al. "Reference values for EORTC QLQ-C30, for metastatic pancreatic cancer (mPC): Enhancing the interpretation of HRQoL scores in the POLO trial." Journal of Clinical Oncology 39, no. 3_suppl (2021): 393. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.393.

Full text

Abstract:

393 Background: Metastatic pancreatic cancer (mPC) and its treatments significantly impact patients’ (pts) health-related quality of life (HRQoL). POLO, a randomized, double-blind, placebo-controlled phase 3 trial evaluated the efficacy of olaparib as maintenance therapy in mPC pts who had not progressed during ≥16 weeks of first-line platinum-based chemo. HRQoL was assessed in POLO using EORTC QLQ-C30. To enhance the interpretation of HRQoL scores in POLO, we derived EORTC QLQ-C30 reference (ref) values for mPC from the literature, as these had not been previously established. Methods: A syst

APA, Harvard, Vancouver, ISO, and other styles

18

Kulikova, A. Kh, A. L. Toigildin, and O. N. Tsapovskaya. "Nutritional regime and biological activity of soil depending on copper contamination and the role of diatomite as a detoxifier." Agrarian science, no. 1 (March 1, 2022): 72–77. http://dx.doi.org/10.32634/0869-8155-2022-355-1-72-77.

Full text

Abstract:

Relevance. Modern agricultural production is characterized by an increase in anthropogenic impact on agrocenoses, which poses a threat to obtaining environmentally safe crop production. Among the toxicants, heavy metals are particularly dangerous, along with pesticides. Metals, including copper, which play a dual role in the “soil — plant” system, are absolutely necessary for plants and at the same time highly toxic when received in excess quantities, deserve special influence in this regard.Methods. The study of the amounts of copper was carried out in microfield experiments with artificial s

APA, Harvard, Vancouver, ISO, and other styles

19

Pinsker, Jordan E., Joon Bok Lee, Eyal Dassau, et al. "Randomized Crossover Comparison of Personalized MPC and PID Control Algorithms for the Artificial Pancreas." Diabetes Care 39, no. 7 (2016): 1135–42. http://dx.doi.org/10.2337/dc15-2344.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Zhang, Xiaojing, Sergio Grammatico, Kostas Margellos, Paul Goulart, and John Lygeros. "Randomized Nonlinear MPC for Uncertain Control-Affine Systems with Bounded Closed-Loop Constraint Violations." IFAC Proceedings Volumes 47, no. 3 (2014): 1649–54. http://dx.doi.org/10.3182/20140824-6-za-1003.02436.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Giommoni, Elisa, Evaristo Maiello, Vanja Vaccaro, et al. "Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)." Current Oncology 28, no. 3 (2021): 1761–72. http://dx.doi.org/10.3390/curroncol28030164.

Full text

Abstract:

Background: Relevant improvement in first-line treatment of metastatic pancreatic cancer (mPC) was provided by FOLFIRINOX and by gemcitabine (gem) plus nab-paclitaxel (Nab-p) regimens. Regardless of the first-line treatment survival benefit, most patients survive less than 1 year. Aim: The objectives of this multicenter phase I/II study were to evaluate as first-line chemotherapy (CT) two modified regimens of FOLFIRINOX, replacing either oxaliplatin (Oxa) or irinotecan with Nab-p, in patients with mPC. Methods: The primary objectives of phase 1 were the definition of the dose limit binations,

APA, Harvard, Vancouver, ISO, and other styles

22

Žilka, Richard, Ondrej Lipták, and Martin Klaučo. "Stochastic Control of Battery Energy Storage System with Hybrid Dynamics." Batteries 10, no. 3 (2024): 75. http://dx.doi.org/10.3390/batteries10030075.

Full text

Abstract:

This paper addresses the control of load demand and power in a battery energy storage system (BESS) with Boolean-type constraints. It employs model predictive control (MPC) tailored for such systems. However, conventional MPC encounters computational challenges in practical applications, including battery storage control, and requires dedicated, mostly licensed solvers. To mitigate this, a solver-free yet efficient, suboptimal method is proposed. This approach involves generating randomized control sequences and assessing their feasibility to ensure adherence to constraints. The sequence with

APA, Harvard, Vancouver, ISO, and other styles

23

Pishvaian, Michael J., Hongkun Wang, Aiwu Ruth He, et al. "A pilot study of molecularly tailored therapy for patients with metastatic pancreatic cancer (MPC)." Journal of Clinical Oncology 33, no. 3_suppl (2015): 329. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.329.

Full text

Abstract:

329 Background: We have entered an era where multiple chemotherapeutic (chemo) agents can be utilized in the treatment (Tx) of patients (pts) with MPC. However, there are no methods for selecting the optimal regimen for any individual pt, and pure empiricism has not proven to be an optimal strategy. Molecular profiling is now widely used, albeit without evidence-based studies linking molecular profiles to Tx choices. Methods: We initiated a pilot study to assess the feasibility of following a simple algorithm, basing Tx on 3 published predictive markers of response to chemo: RRM1 (for gemcitab

APA, Harvard, Vancouver, ISO, and other styles

24

Jiang, Di Maria, Bryan Wong, Alicia K. Morgans, et al. "Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC)." Journal of Clinical Oncology 38, no. 6_suppl (2020): 58. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.58.

Full text

Abstract:

58 Background: HRQOL data are increasingly used to guide patient care and health policy. However, their utility can be compromised by inadequate quality of HRQOL reporting (QHR). We aimed to evaluate QHR in phase III RCTs of mPC. Methods: A systematic review following PRISMA guidelines identified published manuscripts of phase III RCTs of mPC assessing systemic therapies (excluding androgen deprivation therapy and bone targeting agents) between 1990 - 2019. Supplements, references and companion publications were reviewed. QHR was independently quantified using the Minimum Standard Checklist fo

APA, Harvard, Vancouver, ISO, and other styles

25

Karkeet, Riham M., Abdelrahman N. Zekri, Mohamed M. Sayed-Ahmed, et al. "The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial." PLOS ONE 17, no. 12 (2022): e0278282. http://dx.doi.org/10.1371/journal.pone.0278282.

Full text

Abstract:

Aim The role of surgical castration and rosuvastatin treatment on lipid profile and lipid metabolism related markers was evaluated for their prognostic significance in metastatic prostate cancer (mPC) patients. Methods A total of 84 newly diagnosed castrated mPC patients treated with castration were recruited and divided into two groups: Group I served as control (statin non-users) while group II treated with Rosuvastatin (20 mg/day) for 6 months and served as statin users. Prostate specific antigen (PSA), epidermal growth factor receptor (EGFR), Caveolin-1 (CAV1), lipid profile (LDL, HDL, tri

APA, Harvard, Vancouver, ISO, and other styles

26

Packham, David K., Ian R. Fraser, Peter G. Kerr, and Karen R. Segal. "Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study." EBioMedicine 12 (October 2016): 263–69. http://dx.doi.org/10.1016/j.ebiom.2016.09.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Daly, Chris D., Peter Ghosh, Tanya Badal, et al. "333 Intervertebral Disc Repair Following Microdiscectomy Mediated by Pentosan Polysulfate Primed Mesenchymal Progenitor Cells in an Ovine Model." Neurosurgery 64, CN_suppl_1 (2017): 274. http://dx.doi.org/10.1093/neuros/nyx417.333.

Full text

Abstract:

Abstract INTRODUCTION Lumbar microdiscectomy treats neural compression but fails to halt disc degeneration. Consequently, 10 20% of patients develop debilitating back pain and approximately 15% undergo further surgical intervention. In-vitro pre-incubation of mesenchymal precursor cells (MPCs) with pentosan polysulfate (PPS), enhances viability and chondrogenic differentiation, but inhibits osteogenesis. This study investigated the potential of PPS primed mesenchymal precursor cells (pMPCs) in a gelatin scaffold to facilitate disc repair in an ovine model. METHODS Eighteen adult ewes underwent

APA, Harvard, Vancouver, ISO, and other styles

28

Lu, J., H. Deng, R. Tang, et al. "Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for AMG 479 (A479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC)." Journal of Clinical Oncology 29, no. 4_suppl (2011): 263. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.263.

Full text

Abstract:

263 Background: A479 is an investigational, fully human monoclonal antibody against IGF1R. In a phase II study, 125 pts with mPC were randomized 1:1:1 to A479, placebo (P), or conatumumab in combination with G. Addition of A479 (12 mg/kg IV, Q2W) to G (1000 mg/m2) showed evidence of improved OS and PFS (Kindler, JCO 2010:28 abstr 4035). An E-R analysis was done to inform P3 dose selection for A479. Methods: A population PK model of A479 was constructed using data from multiple studies. An E-R analysis was performed with pts from the A479+G and P+G arms (∼40 pts/arm). The effect of estimated st

APA, Harvard, Vancouver, ISO, and other styles

29

Ustinova, T. V., L. V. Bolotina, A. A. Paichadze, A. A. Kachmazov, A. A. Fedenko, and A. D. Kaprin. "Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience." Meditsinskiy sovet = Medical Council, no. 20 (December 11, 2021): 130–36. http://dx.doi.org/10.21518/2079-701x-2021-20-130-136.

Full text

Abstract:

Prostate cancer is one of the most common neoplasms in men. It currently ranks second in Russian Federation amongst male population in overall number of cases after only lung cancer and third in cancer mortality. Prostate cancer is rarely diagnosed in patients younger than 40 years old, with overage age of diagnosis being between 50 and 70 years. A lot of different new treatment options were developed in the last decade for patients with metastatic prostate cancer (mPC). Despite androgen-deprivation remaining the standard of therapy, it has been proven that the addition of cytotoxic and hormon

APA, Harvard, Vancouver, ISO, and other styles

30

Patel, Timil, Thejal Srikumar, Joseph Anthony Miccio, et al. "Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System." Journal of Clinical Oncology 38, no. 4_suppl (2020): 769. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.769.

Full text

Abstract:

769 Background: FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GN) are established first line (1L) therapies for metastatic pancreatic cancer (MPC) but real-world data on their comparative effectiveness is limited. Methods: All cases of MPC treated with 1L FFX or GN at Yale Smilow Cancer Hospital and the affiliated community care centers (CCC) from January 2011 – April 2019 were reviewed. Patient (pt) demographics, prior therapy, initial and subsequent dose reductions (DR), time to treatment discontinuation (TTD), overall survival (OS), and second line (2L) treatment data were manually

APA, Harvard, Vancouver, ISO, and other styles

31

Tsang, Erica S., Hui-Li Wong, Ying Wang, et al. "Outcomes and characteristics of patients receiving second-line therapy for advanced pancreatic cancer." Journal of Clinical Oncology 36, no. 4_suppl (2018): 435. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.435.

Full text

Abstract:

435 Background: Recent trials have demonstrated improved outcomes in the 1st-line treatment of advanced pancreatic cancer (APC). However, there is limited randomized data to guide 2nd-line chemotherapy (CT) selection. We aimed to characterize predictors and outcomes of 2nd-line CT in patients (pts) with APC. Methods: We identified all pts with APC (locally advanced (LAPC) or metastatic (MPC)) who received ≥1 cycle of 1st-line CT between January 1, 2012 and December 31, 2015 across 6 centers in British Columbia, Canada. Baseline characteristics and survival outcomes were summarized. Results: Of

APA, Harvard, Vancouver, ISO, and other styles

32

Dorman, Klara, Stefan Hubert Boeck, Karel Caca, et al. "Alternating application of gemcitabine/nab-paclitaxel (Gem/nab-Pac) and Gem monotherapy or continuous application of Gem/nab-Pac after induction treatment for first-line treatment of metastatic pancreatic cancer (mPC): First results from the randomized phase 2 ALPACA study from the German AIO study group (AIO-PAK-0114)." Journal of Clinical Oncology 42, no. 3_suppl (2024): 605. http://dx.doi.org/10.1200/jco.2024.42.3_suppl.605.

Full text

Abstract:

605 Background: The aim of the ALPACA study was to investigate whether improved overall tolerability accompanied by prolonged treatment duration and increased efficacy can be achieved by alternating treatment cycles of Gem/nab-Pac and Gem monotherapy compared to standard continuous Gem/nab-Pac after a 3-month induction phase in patients with mPC. Methods: The randomized, multicenter phase 2 ALPACA trial of the German AIO study group enrolled patients with confirmed mPC in the first-line setting. After an induction phase with 3 cycles of standard dose Gem/nab-Pac (Gem 1000 mg/m2 and nab-Pac 125

APA, Harvard, Vancouver, ISO, and other styles

33

Swami, Umang, Jennifer Anne Sinnott, Ben Haaland, et al. "Overall survival (OS) with docetaxel (D) vs novel hormonal therapy (NHT) with abiraterone (A) or enzalutamide (E) after a prior NHT in patients (Pts) with metastatic prostate cancer (mPC): Results from a real-world dataset." Journal of Clinical Oncology 38, no. 15_suppl (2020): 5537. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5537.

Full text

Abstract:

5537 Background: NHT (A and E) are approved first-line (1L) treatment (Rx) for mPC. After progression on NHT, Rx include either alternate NHT or D. However, OS from a randomized trial comparing NHT vs D after progression on 1L NHT has not been reported. Methods: Pts data were extracted from the Flatiron Health EHR-derived de-identified database. Inclusion: diagnosis of mPC; 1L Rx with single agent A or E only, single-agent Rx with alternate NHT (E or A) or D in second line (2L). Exclusion: > 180 days between date of diagnosis of mPC and date of next visit to ensure Pts were actively engaged

APA, Harvard, Vancouver, ISO, and other styles

34

Park, Wungki, Eileen Mary O'Reilly, Junji Furuse, et al. "Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study." Journal of Clinical Oncology 41, no. 4_suppl (2023): TPS782. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.tps782.

Full text

Abstract:

TPS782 Background: GN is a first-line treatment option for patients (pts) with mPC. Poor prognosis and low 5-year survival rate ( < 5%) with mPC highlight the need for new therapeutics. Claudin 18.2 (CLDN18.2), a tight junction protein expressed exclusively on normal gastric epithelial cells, is maintained during malignant transformation in gastric cancers and is frequently expressed in some carcinomas from organs that do not normally express it, such as pancreatic cancer. Zolbetuximab, a chimeric IgG1 monoclonal antibody, binds to CLDN18.2 and mediates tumor cell death through antibody-dep

APA, Harvard, Vancouver, ISO, and other styles

35

Chiorean, E. Gabriela, Katherine A. Guthrie, Philip Agop Philip, et al. "Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513." Journal of Clinical Oncology 37, no. 15_suppl (2019): 4014. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4014.

Full text

Abstract:

4014 Background: PC is characterized by DNA Damage Repair (DDR) deficiencies, including in BRCA1/2, ATM, and FANC genes. Given preclinical synergism between veliparib with irinotecan, safety and preliminary efficacy, we designed a randomized phase II study of mFOLFIRI (no 5-FU bolus) + veliparib vs FOLFIRI alone for 2nd line mPC patients (pts). Methods: Eligible pts had mPC, adequate organ function, ECOG PS 0-1, and 1 prior non-irinotecan systemic therapy.143 pts were to be randomized (1:1) to veliparib vs control. Primary endpoint was overall survival (OS). All pts had blood and tumor biopsie

APA, Harvard, Vancouver, ISO, and other styles

36

Chiorean, E. Gabriela, Shannon McDonough, Philip Agop Philip, et al. "Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513." Journal of Clinical Oncology 35, no. 15_suppl (2017): TPS4147. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.tps4147.

Full text

Abstract:

TPS4147 Background: PC is characterized by multiple DNA repair defects, including in BRCA1/ 2, and other homologous recombination (HR) genes such as FANC, ATM, ATR (Waddell N, Nature 2015). Folinic acid/5-fluorouracil/ irinotecan (FOLFIRI) is a 2nd line therapy option in mPC, but overall survival (OS) averages only 6 mos (Yoo C, Br J Cancer 2009). It is known that PARP facilitates repair from topoisomerase 1-associated DNA damage, and that preclinically PARP inhibitors (PARPi) increase DNA breaks from camptothecins, resulting in synergistic antitumor effects (Smith LM, Clin Cancer Res 2005, Da

APA, Harvard, Vancouver, ISO, and other styles

37

Klein-Brill, Avital, Shlomit Amar-Farkash, Gabriella Lawrence, Eric Andrew Collisson, Michael Jordan Fisch, and Dvir Aran. "Real-world data comparing FOLFIRINOX versus gemcitabine nab-paclitaxel as first-line treatment of metastatic pancreatic ductal adenocarcinoma patients in the United States." Journal of Clinical Oncology 40, no. 16_suppl (2022): e16271-e16271. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e16271.

Full text

Abstract:

e16271 Background: The common first-line therapies for metastatic adenocarcinoma of the pancreas (mPC) are FOLFIRINOX and gemcitabine plus nab-paclitaxel (Gem-Nab-P). However, these treatments have not been directly compared in a clinical trial and comparative real-world data analyses on their effectiveness are limited. Using real-world data, we evaluated the impact on overall survival and post-treatment hospitalizations of 1L FOLFIRINOX vs. Gem-Nab-P in individuals with mPC. Methods: We performed a retrospective cohort study of 1L treatment of patients with mPC between 1/2015 and 6/2020, util

APA, Harvard, Vancouver, ISO, and other styles

38

Klein-Brill, Avital, Shlomit Amar-Farkash, Gabriella Lawrence, Eric Andrew Collisson, Michael Jordan Fisch, and Dvir Aran. "Real-world data comparing FOLFIRINOX versus gemcitabine nab-paclitaxel as first-line treatment of metastatic pancreatic ductal adenocarcinoma patients in the United States." Journal of Clinical Oncology 40, no. 16_suppl (2022): e16271-e16271. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e16271.

Full text

Abstract:

e16271 Background: The common first-line therapies for metastatic adenocarcinoma of the pancreas (mPC) are FOLFIRINOX and gemcitabine plus nab-paclitaxel (Gem-Nab-P). However, these treatments have not been directly compared in a clinical trial and comparative real-world data analyses on their effectiveness are limited. Using real-world data, we evaluated the impact on overall survival and post-treatment hospitalizations of 1L FOLFIRINOX vs. Gem-Nab-P in individuals with mPC. Methods: We performed a retrospective cohort study of 1L treatment of patients with mPC between 1/2015 and 6/2020, util

APA, Harvard, Vancouver, ISO, and other styles

39

Schroeder, Brett A., Margaret T. Mandelson, and Vincent J. Picozzi. "Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Safety and Effect." Cancers 15, no. 23 (2023): 5588. http://dx.doi.org/10.3390/cancers15235588.

Full text

Abstract:

Background: Both gemcitabine- and 5-fluorouracil (5-FU)-based chemotherapy regimens have demonstrated efficacy in metastatic pancreatic cancer (MPC). Alternating these regimens may reduce toxicity, slow resistant cancer biology emergence, and provide a platform for the addition of other therapeutic agents. Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) in MPC has previously been reported at our own institution and elsewhere. An extension of our institutional observations is reported here. Methods: Patient eligibility required the following: biopsy-proven d

APA, Harvard, Vancouver, ISO, and other styles

40

Nicolopoulos, Konstance, Magdalena Ruth Moshi, Danielle Stringer, Ning Ma, Mathias Jenal, and Thomas Vreugdenburg. "OP70 Treating Patients With Hormone-Sensitive Cancer On Endocrine Therapy With Denosumab (Prolia®): A Systematic Review And Network Meta-Analysis." International Journal of Technology Assessment in Health Care 39, S1 (2023): S19. http://dx.doi.org/10.1017/s0266462323000946.

Full text

Abstract:

IntroductionPatients receiving endocrine therapy for hormone-sensitive cancers, such as men with prostate cancer (MPC) on hormone ablation therapy (HAT) and women with breast cancer (WBC) on adjuvant aromatase inhibitor therapy (AAIT), have an increased risk of developing osteoporosis. The aim of this study was to compare the safety and effectiveness of denosumab (Prolia®) with selective estrogen receptor modulators (SERMs) (raloxifene and bazedoxifene), bisphosphonates (zoledronate, ibandronate, alendronate, and risedronate), and placebo for the treatment of osteoporosis in patients receiving

APA, Harvard, Vancouver, ISO, and other styles

41

Barrera, Ivan, Sabina Hamalova, Jill Ranger, et al. "Folfirinox (FFX) versus gemcitabine with nab‐paclitaxel (GNP) in the first line treatment (1LTx) of metastatic pancreatic cancer (mPC): A tertiary center experience." Journal of Clinical Oncology 36, no. 4_suppl (2018): 414. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.414.

Full text

Abstract:

414 Background: The efficacy of FFX and GNP as 1LTx of mPC were established in phase 3 trials against Gemcitabine alone. However, no head‐to‐head trial has been performed. This analysis was conducted to compare the use of the two regimens in the 1LTx of mPC patients (pts). Methods: Retrospective study collected data of pts diagnosed with mPC (ECOG 0‐1) that received FFX or GNP as 1LTx at the Jewish General Hospital between 2010‐2016. Pt selection for 1LTx was based in ASCO Guidelines 2016 Criteria (AGC2016). Progression free survival (PFS) and overall survival (OS) were estimated using a Kapla

APA, Harvard, Vancouver, ISO, and other styles

42

Park, Wungki, Eileen Mary O'Reilly, Junji Furuse, Futoshi Kunieda, Fei Jie, and Hedy L. Kindler. "Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2–positive metastatic pancreatic cancer (mPC)." Journal of Clinical Oncology 38, no. 15_suppl (2020): TPS4667. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps4667.

Full text

Abstract:

TPS4667 Background: Combinations of folinic acid, fluorouracil (5-FU), irinotecan, and oxaliplatin (FOLFIRINOX) along with GN are standard first-line treatment options for mPC. Despite treatment advances, mPC has a poor prognosis with a 5-year survival rate of < 5%, emphasizing an urgent need for new targeted therapeutics. Claudin 18.2 (CLDN18.2) is a tight junction protein restricted to normal gastric mucosa cells; however, in the context of malignant transformation, CLDN18.2 is frequently expressed in carcinomas derived from organs that do not normally express it, such as pancreatic adeno

APA, Harvard, Vancouver, ISO, and other styles

43

Hurwitz, Herbert, Eric Van Cutsem, Johanna C. Bendell, et al. "Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2)." Journal of Clinical Oncology 35, no. 4_suppl (2017): 343. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.343.

Full text

Abstract:

343 Background: The JAK-STAT pathway plays a role in the pathogenesis of PC. In a phase 2 study, the JAK1/2 inhibitor Rux + C improved OS vs C alone in mPC pts with evidence of systemic inflammation. Methods: In two phase 3 studies, advanced/mPC pts with only 1 prior chemotherapy regimen and C-reactive protein > 10mg/L were randomized to 21-day cycles of Rux 15 mg BID + C 2000 mg/m2/d (day 1-14) vs placebo (Pb) BID + C 2000 mg/m2/d (day 1-14). The primary endpoint was OS. The studies were terminated early based on efficacy findings of a planned interim analysis for J1, with J2 enrollment in

APA, Harvard, Vancouver, ISO, and other styles

44

Chen, Chun-Hung, Ling-Chun Wang, Tzu-Chiao Ma, and Yuan-Han Yang. "A Walk-In Screening of Dementia in the General Population in Taiwan." Scientific World Journal 2014 (2014): 1–5. http://dx.doi.org/10.1155/2014/243738.

Full text

Abstract:

Alzheimer's disease (AD) has increased in its prevalence due to the increasing aged population. Currently there is no updated data on the prevalence of dementia including its very mild stage in Taiwan. Under the extensive coverage of Mentality Protection Center (MPC), Fo Guang Shan, Taiwan, the volunteers of MPC have conducted the medicine-related services and the screening of dementia by AD8 (ascertainment of dementia 8) that can screen the dementia even at its very mild stage in general population in all Taiwan. From 2011 to 2013, in total, 2,171 participants, 368 in the northern, 549 in the

APA, Harvard, Vancouver, ISO, and other styles

45

Adams, Samuel, Chaitali Choudhary, Martine de Cock, et al. "Privacy-preserving training of tree ensembles over continuous data." Proceedings on Privacy Enhancing Technologies 2022, no. 2 (2022): 205–26. http://dx.doi.org/10.2478/popets-2022-0042.

Full text

Abstract:

Abstract Most existing Secure Multi-Party Computation (MPC) protocols for privacy-preserving training of decision trees over distributed data assume that the features are categorical. In real-life applications, features are often numerical. The standard “in the clear” algorithm to grow decision trees on data with continuous values requires sorting of training examples for each feature in the quest for an optimal cut-point in the range of feature values in each node. Sorting is an expensive operation in MPC, hence finding secure protocols that avoid such an expensive step is a relevant problem

APA, Harvard, Vancouver, ISO, and other styles

46

Chiorean, Elena Gabriela, Winson Y. Cheung, Guido Giordano, George Kim, and Salah-Eddin Al-Batran. "Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review." Therapeutic Advances in Medical Oncology 11 (January 2019): 175883591985036. http://dx.doi.org/10.1177/1758835919850367.

Full text

Abstract:

Background: No clinical trial has directly compared nab-paclitaxel/gemcitabine (nab-P/G) with FOLFIRINOX (fluorouracil/leucovorin/oxaliplatin/irinotecan) in metastatic or advanced pancreatic cancer (mPC or aPC). We conducted a systematic review of real-world studies comparing these regimens in the first-line setting. Methods: Embase and MEDLINE databases through 22 January 2019, and Gastrointestinal Cancers Symposium 2019 abstracts were searched for real-world, retrospective studies comparing first-line nab-P/G versus FOLFIRINOX in mPC or aPC that met specific parameters. Studies with radiothe

APA, Harvard, Vancouver, ISO, and other styles

47

Martinez, Imanol, Kenneth Kernan, Piotr Piasecki, et al. "A novel abiraterone acetate oral suspension for patients with metastatic prostate cancer: An open-label, phase 3, randomized trial." Journal of Clinical Oncology 41, no. 16_suppl (2023): 5052. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5052.

Full text

Abstract:

5052 Background: Abiraterone acetate (AA) is a first-line oral hormone therapy for metastatic prostate cancer (mPC), but the licensed formulation is limited by large tablet size, requirement to take on an empty stomach, and pharmacokinetic variability. TAVT-45, a novel formulation of AA granules for oral suspension, offers improved oral bioavailability (allowing dose reduction), decreased food effect, and may provide an option for the ~20-30% of patients with dysphagia. This Phase 3, open-label global study (NCT04887506) aimed to establish therapeutic equivalence between TAVT-45 granules and r

APA, Harvard, Vancouver, ISO, and other styles

48

Phillips, Cameron, Seanthel Delos Santos, Robert Mason, and Urban Emmenegger. "A survey to determine patients’ (pts) opinions of a clinical trial (CT) comparing intermittent (int) versus continuous (cont) androgen receptor signaling inhibitor (ARSi) therapy for the treatment of advanced prostate cancer." Journal of Clinical Oncology 37, no. 7_suppl (2019): 295. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.295.

Full text

Abstract:

295 Background: Several therapies have shown a survival benefit and improvements in pt-reported quality of life in metastatic prostate cancer (mPC) including ARSis, such as abiraterone (A) and enzalutamide (E). While both are fairly well tolerated, there is a wide range of side effects associated with them. In addition, both of these medications are costly. The purpose of this study was to obtain pts’ opinions regarding potential participation in a randomized CT comparing int to cont treatment with A and E. Methods: We approached ambulatory pts diagnosed with mPC between August 2018 and Octobe

APA, Harvard, Vancouver, ISO, and other styles

49

Goldstein, David, Robert Hassan El Maraghi, Pascal Hammel, et al. "Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas." Journal of Clinical Oncology 32, no. 3_suppl (2014): 178. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.178.

Full text

Abstract:

178^ Background: In the phase III MPACT trial, nab-paclitaxel (nab-P) + gemcitabine (G) was tolerable and demonstrated superiority to G alone for all efficacy endpoints in pts with metastatic pancreatic cancer (MPC). nab-P + G vs G alone met the study’s primary endpoint by demonstrating a significant improvement in overall survival (OS; median 8.5 vs 6.7 months; HR 0.72; 95% CI, 0.617 - 0.835; P < 0.001) and the secondary endpoints of progression-free survival (PFS; median 5.5 vs 3.7 months; HR 0.69; 95% CI, 0.581 - 0.821; P < 0.001) and overall response rate (ORR; 23% vs 7%; P < 0.00

APA, Harvard, Vancouver, ISO, and other styles

50

Bradford, Eric, and Lars Imsland. "Expectation constrained stochastic nonlinear model predictive control of a bioreactor." Computer Aided Chemical Engineering 40 (October 25, 2017): 1621–26. https://doi.org/10.5281/zenodo.1036782.

Full text

Abstract:

Nonlinear model predictive control is a popular control approach for highly nonlinear and unsteady state processes, which however can fail due to unaccounted uncertainties. This paper proposes to apply a sample-average approach to solve the general stochastic nonlinear model predictive control problem to handle probabilistic uncertainties. Each sample represents a nonlinear simulation, which is expensive. Therefore, variance-reduction methods were systematically compared to lower the necessary number of samples. The method was shown to perform well on a semi-batch bioreactor case-study compare

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!